BioNano Genomics Inc vs Strategy Inc. — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Strategy Inc. trades at $95.76 (market cap $37.84B). The key difference: Strategy Inc. is far larger — about 2770.1× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.
| BNGO | MSTR | |
|---|---|---|
Market Cap | $13.66M | $37.84B |
Sector | Health | Technology |
52-Week High | $4.92 | $394.39 |
52-Week Low | $1.06 | $82.31 |
Enterprise Value | $16.26M | $56.61B |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
MSTR trades at $95.25, down 2.14% with a bearish technical signal. The company reported Q2 2026 EPS of -$24.45, missing expectations of -$2.19, continuing a trend of significant earnings misses. Despite a 62% analyst buy rating and $210 consensus price target, fundamentals show deep losses with -$3.85B net income and -6,102.96% net margin in 2025. Recent news highlights Bitcoin-related volatility and strategic shifts in the company's treasury management approach.
The stock faces substantial fundamental challenges with persistent losses and negative cash flow from operations, though Wall Street maintains bullish long-term targets. Key risks include execution challenges, Bitcoin price exposure, and competitive pressures in the software analytics market. The disconnect between analyst optimism and operational performance creates significant uncertainty for investors.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →